

Otelixizumab

Cat. No.:	HY-P99211
CAS No.:	881191-44-2
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes ^[1] .									
IC₅₀ & Target	CD3 ^[1]									
In Vitro	<p>Otelixizumab (ChAglyCD3) has a dose-dependent accumulation and a half-life of about 1.5 days^[2]. Otelixizumab targets the ε-chain of the CD3 T-lymphocyte surface receptor, which facilitates the activation of the autoreactive T-lymphocytes responsible for beta cell destruction^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>Otelixizumab (ChAglyCD3) (100 µg/mouse; i.v.; once) results in durable disease remission dependent on transferable T cell-mediated tolerance in diabetic transgenic mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>BALB/c-huCD3e mice carrying the human CD3e chain^[1]</td> </tr> <tr> <td>Dosage:</td> <td>100 µg/mouse</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection, once</td> </tr> <tr> <td>Result:</td> <td>Induced secretion of lower amounts of IL-6. Exhibited up-regulation of regulatory T cells.</td> </tr> </table>		Animal Model:	BALB/c-huCD3e mice carrying the human CD3e chain ^[1]	Dosage:	100 µg/mouse	Administration:	Intravenous injection, once	Result:	Induced secretion of lower amounts of IL-6. Exhibited up-regulation of regulatory T cells.
Animal Model:	BALB/c-huCD3e mice carrying the human CD3e chain ^[1]									
Dosage:	100 µg/mouse									
Administration:	Intravenous injection, once									
Result:	Induced secretion of lower amounts of IL-6. Exhibited up-regulation of regulatory T cells.									

REFERENCES

- [1]. Kuhn C, et al. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. *Sci Transl Med.* 2011 Feb 2;3(68):68ra10.
- [2]. Guglielmi C, et al. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus. *Expert Opin Biol Ther.* 2016 Jun;16(6):841-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA